Acute lysyl oxidase inhibition alters microvascular function in normotensive but not hypertensive men and women

The lysyl oxidase (LOX) family of enzymes regulates collagen cross-linking. LOX is upregulated in hypertension, increasing vascular stiffness. In vivo human research is sparse, as long-term LOX inhibition in animals causes vascular instability. Our aim was to evaluate the effects of LOX inhibition o...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of physiology. Heart and circulatory physiology Vol. 314; no. 3; pp. H424 - H433
Main Authors Craighead, Daniel H., Wang, Huilei, Santhanam, Lakshmi, Alexander, Lacy M.
Format Journal Article
LanguageEnglish
Published United States American Physiological Society 01.03.2018
SeriesExtracellular Matrix in Cardiovascular Pathophysiology
Subjects
Online AccessGet full text
ISSN0363-6135
1522-1539
1522-1539
DOI10.1152/ajpheart.00521.2017

Cover

Loading…
Abstract The lysyl oxidase (LOX) family of enzymes regulates collagen cross-linking. LOX is upregulated in hypertension, increasing vascular stiffness. In vivo human research is sparse, as long-term LOX inhibition in animals causes vascular instability. Our aim was to evaluate the effects of LOX inhibition on cutaneous microvascular function to determine whether LOX function was upregulated in hypertensive humans. Four intradermal microdialysis fibers were placed in the forearm of 10 young [age: 24 ± 1 yr, mean arterial pressure (MAP): 87 ± 2 mmHg], 10 normotensive (age: 50 ± 2 yr, MAP: 84 ± 1 mmHg), and 10 hypertensive (age: 53 ± 2 yr, MAP: 112 ± 2 mmHg) subjects. Two sites were perfused with 10 mM β-aminopropionitrile (BAPN) to inhibit LOX. The remaining two sites were perfused with lactated Ringer solution (control). A norepinephrine dose response (10 -10 M) was performed to examine receptor-mediated vasoconstrictor function. A sodium nitroprusside dose response (10 -10 M) was performed to examine vascular smooth muscle vasodilator function. Red blood cell flux was measured via laser-Doppler flowmetry and normalized to cutaneous vascular conductance (flux/MAP). LogEC values were calculated to determine changes in vasosensitivity. Skin tissue samples were analyzed for both extracellular matrix-bound and soluble LOX. LOX inhibition augmented vasoconstrictor sensitivity in young (control: -6.0 and BAPN: -7.1, P = 0.03) and normotensive (control: -4.8 and BAPN: -7.0, P = 0.01) but not hypertensive (control: -6.0 and BAPN: -6.1, P = 0.79) men and women. Relative to young subjects, extracellular matrix-bound LOX expression was higher in hypertensive subjects (young: 100 ± 8 and hypertensive: 162 ± 8, P = 0.002). These results suggest that upregulated LOX may contribute to the vascular stiffness and microvascular dysfunction characteristic in hypertension. NEW & NOTEWORTHY Matrix-bound lysyl oxidase (LOX) and LOX-like 2 expression are upregulated in the microvasculature of hypertensive men and women. Microvascular responsiveness to exogenous stimuli is altered with localized LOX inhibition in healthy men and women but not hypertensive adults. The LOX family differentially affects microvascular function in hypertensive and normotensive men and women.
AbstractList The lysyl oxidase (LOX) family of enzymes regulates collagen cross-linking. LOX is upregulated in hypertension, increasing vascular stiffness. In vivo human research is sparse, as long-term LOX inhibition in animals causes vascular instability. Our aim was to evaluate the effects of LOX inhibition on cutaneous microvascular function to determine whether LOX function was upregulated in hypertensive humans. Four intradermal microdialysis fibers were placed in the forearm of 10 young [age: 24 ± 1 yr, mean arterial pressure (MAP): 87 ± 2 mmHg], 10 normotensive (age: 50 ± 2 yr, MAP: 84 ± 1 mmHg), and 10 hypertensive (age: 53 ± 2 yr, MAP: 112 ± 2 mmHg) subjects. Two sites were perfused with 10 mM β-aminopropionitrile (BAPN) to inhibit LOX. The remaining two sites were perfused with lactated Ringer solution (control). A norepinephrine dose response (10-12-10-2 M) was performed to examine receptor-mediated vasoconstrictor function. A sodium nitroprusside dose response (10-8-10-1.3M) was performed to examine vascular smooth muscle vasodilator function. Red blood cell flux was measured via laser-Doppler flowmetry and normalized to cutaneous vascular conductance (flux/MAP). LogEC50 values were calculated to determine changes in vasosensitivity. Skin tissue samples were analyzed for both extracellular matrix-bound and soluble LOX. LOX inhibition augmented vasoconstrictor sensitivity in young (control: -6.0 and BAPN: -7.1, P = 0.03) and normotensive (control: -4.8 and BAPN: -7.0, P = 0.01) but not hypertensive (control: -6.0 and BAPN: -6.1, P = 0.79) men and women. Relative to young subjects, extracellular matrix-bound LOX expression was higher in hypertensive subjects (young: 100 ± 8 and hypertensive: 162 ± 8, P = 0.002). These results suggest that upregulated LOX may contribute to the vascular stiffness and microvascular dysfunction characteristic in hypertension.
The lysyl oxidase (LOX) family of enzymes regulates collagen cross-linking. LOX is upregulated in hypertension, increasing vascular stiffness. In vivo human research is sparse, as long-term LOX inhibition in animals causes vascular instability. Our aim was to evaluate the effects of LOX inhibition on cutaneous microvascular function to determine whether LOX function was upregulated in hypertensive humans. Four intradermal microdialysis fibers were placed in the forearm of 10 young [age: 24 ± 1 yr, mean arterial pressure (MAP): 87 ± 2 mmHg], 10 normotensive (age: 50 ± 2 yr, MAP: 84 ± 1 mmHg), and 10 hypertensive (age: 53 ± 2 yr, MAP: 112 ± 2 mmHg) subjects. Two sites were perfused with 10 mM β-aminopropionitrile (BAPN) to inhibit LOX. The remaining two sites were perfused with lactated Ringer solution (control). A norepinephrine dose response (10 −12 −10 −2 M) was performed to examine receptor-mediated vasoconstrictor function. A sodium nitroprusside dose response (10 −8 −10 −1.3 M) was performed to examine vascular smooth muscle vasodilator function. Red blood cell flux was measured via laser-Doppler flowmetry and normalized to cutaneous vascular conductance (flux/MAP). LogEC 50 values were calculated to determine changes in vasosensitivity. Skin tissue samples were analyzed for both extracellular matrix-bound and soluble LOX. LOX inhibition augmented vasoconstrictor sensitivity in young (control: −6.0 and BAPN: −7.1, P = 0.03) and normotensive (control: −4.8 and BAPN: −7.0, P = 0.01) but not hypertensive (control: −6.0 and BAPN: −6.1, P = 0.79) men and women. Relative to young subjects, extracellular matrix-bound LOX expression was higher in hypertensive subjects (young: 100 ± 8 and hypertensive: 162 ± 8, P = 0.002). These results suggest that upregulated LOX may contribute to the vascular stiffness and microvascular dysfunction characteristic in hypertension. NEW & NOTEWORTHY Matrix-bound lysyl oxidase (LOX) and LOX-like 2 expression are upregulated in the microvasculature of hypertensive men and women. Microvascular responsiveness to exogenous stimuli is altered with localized LOX inhibition in healthy men and women but not hypertensive adults. The LOX family differentially affects microvascular function in hypertensive and normotensive men and women.
The lysyl oxidase (LOX) family of enzymes regulates collagen cross-linking. LOX is upregulated in hypertension, increasing vascular stiffness. In vivo human research is sparse, as long-term LOX inhibition in animals causes vascular instability. Our aim was to evaluate the effects of LOX inhibition on cutaneous microvascular function to determine whether LOX function was upregulated in hypertensive humans. Four intradermal microdialysis fibers were placed in the forearm of 10 young [age: 24 ± 1 yr, mean arterial pressure (MAP): 87 ± 2 mmHg], 10 normotensive (age: 50 ± 2 yr, MAP: 84 ± 1 mmHg), and 10 hypertensive (age: 53 ± 2 yr, MAP: 112 ± 2 mmHg) subjects. Two sites were perfused with 10 mM β-aminopropionitrile (BAPN) to inhibit LOX. The remaining two sites were perfused with lactated Ringer solution (control). A norepinephrine dose response (10 -10 M) was performed to examine receptor-mediated vasoconstrictor function. A sodium nitroprusside dose response (10 -10 M) was performed to examine vascular smooth muscle vasodilator function. Red blood cell flux was measured via laser-Doppler flowmetry and normalized to cutaneous vascular conductance (flux/MAP). LogEC values were calculated to determine changes in vasosensitivity. Skin tissue samples were analyzed for both extracellular matrix-bound and soluble LOX. LOX inhibition augmented vasoconstrictor sensitivity in young (control: -6.0 and BAPN: -7.1, P = 0.03) and normotensive (control: -4.8 and BAPN: -7.0, P = 0.01) but not hypertensive (control: -6.0 and BAPN: -6.1, P = 0.79) men and women. Relative to young subjects, extracellular matrix-bound LOX expression was higher in hypertensive subjects (young: 100 ± 8 and hypertensive: 162 ± 8, P = 0.002). These results suggest that upregulated LOX may contribute to the vascular stiffness and microvascular dysfunction characteristic in hypertension. NEW & NOTEWORTHY Matrix-bound lysyl oxidase (LOX) and LOX-like 2 expression are upregulated in the microvasculature of hypertensive men and women. Microvascular responsiveness to exogenous stimuli is altered with localized LOX inhibition in healthy men and women but not hypertensive adults. The LOX family differentially affects microvascular function in hypertensive and normotensive men and women.
The lysyl oxidase (LOX) family of enzymes regulates collagen cross-linking. LOX is upregulated in hypertension, increasing vascular stiffness. In vivo human research is sparse, as long-term LOX inhibition in animals causes vascular instability. Our aim was to evaluate the effects of LOX inhibition on cutaneous microvascular function to determine whether LOX function was upregulated in hypertensive humans. Four intradermal microdialysis fibers were placed in the forearm of 10 young [age: 24 ± 1 yr, mean arterial pressure (MAP): 87 ± 2 mmHg], 10 normotensive (age: 50 ± 2 yr, MAP: 84 ± 1 mmHg), and 10 hypertensive (age: 53 ± 2 yr, MAP: 112 ± 2 mmHg) subjects. Two sites were perfused with 10 mM β-aminopropionitrile (BAPN) to inhibit LOX. The remaining two sites were perfused with lactated Ringer solution (control). A norepinephrine dose response (10-12-10-2 M) was performed to examine receptor-mediated vasoconstrictor function. A sodium nitroprusside dose response (10-8-10-1.3 M) was performed to examine vascular smooth muscle vasodilator function. Red blood cell flux was measured via laser-Doppler flowmetry and normalized to cutaneous vascular conductance (flux/MAP). LogEC50 values were calculated to determine changes in vasosensitivity. Skin tissue samples were analyzed for both extracellular matrix-bound and soluble LOX. LOX inhibition augmented vasoconstrictor sensitivity in young (control: -6.0 and BAPN: -7.1, P = 0.03) and normotensive (control: -4.8 and BAPN: -7.0, P = 0.01) but not hypertensive (control: -6.0 and BAPN: -6.1, P = 0.79) men and women. Relative to young subjects, extracellular matrix-bound LOX expression was higher in hypertensive subjects (young: 100 ± 8 and hypertensive: 162 ± 8, P = 0.002). These results suggest that upregulated LOX may contribute to the vascular stiffness and microvascular dysfunction characteristic in hypertension. NEW & NOTEWORTHY Matrix-bound lysyl oxidase (LOX) and LOX-like 2 expression are upregulated in the microvasculature of hypertensive men and women. Microvascular responsiveness to exogenous stimuli is altered with localized LOX inhibition in healthy men and women but not hypertensive adults. The LOX family differentially affects microvascular function in hypertensive and normotensive men and women.The lysyl oxidase (LOX) family of enzymes regulates collagen cross-linking. LOX is upregulated in hypertension, increasing vascular stiffness. In vivo human research is sparse, as long-term LOX inhibition in animals causes vascular instability. Our aim was to evaluate the effects of LOX inhibition on cutaneous microvascular function to determine whether LOX function was upregulated in hypertensive humans. Four intradermal microdialysis fibers were placed in the forearm of 10 young [age: 24 ± 1 yr, mean arterial pressure (MAP): 87 ± 2 mmHg], 10 normotensive (age: 50 ± 2 yr, MAP: 84 ± 1 mmHg), and 10 hypertensive (age: 53 ± 2 yr, MAP: 112 ± 2 mmHg) subjects. Two sites were perfused with 10 mM β-aminopropionitrile (BAPN) to inhibit LOX. The remaining two sites were perfused with lactated Ringer solution (control). A norepinephrine dose response (10-12-10-2 M) was performed to examine receptor-mediated vasoconstrictor function. A sodium nitroprusside dose response (10-8-10-1.3 M) was performed to examine vascular smooth muscle vasodilator function. Red blood cell flux was measured via laser-Doppler flowmetry and normalized to cutaneous vascular conductance (flux/MAP). LogEC50 values were calculated to determine changes in vasosensitivity. Skin tissue samples were analyzed for both extracellular matrix-bound and soluble LOX. LOX inhibition augmented vasoconstrictor sensitivity in young (control: -6.0 and BAPN: -7.1, P = 0.03) and normotensive (control: -4.8 and BAPN: -7.0, P = 0.01) but not hypertensive (control: -6.0 and BAPN: -6.1, P = 0.79) men and women. Relative to young subjects, extracellular matrix-bound LOX expression was higher in hypertensive subjects (young: 100 ± 8 and hypertensive: 162 ± 8, P = 0.002). These results suggest that upregulated LOX may contribute to the vascular stiffness and microvascular dysfunction characteristic in hypertension. NEW & NOTEWORTHY Matrix-bound lysyl oxidase (LOX) and LOX-like 2 expression are upregulated in the microvasculature of hypertensive men and women. Microvascular responsiveness to exogenous stimuli is altered with localized LOX inhibition in healthy men and women but not hypertensive adults. The LOX family differentially affects microvascular function in hypertensive and normotensive men and women.
Author Santhanam, Lakshmi
Craighead, Daniel H.
Wang, Huilei
Alexander, Lacy M.
Author_xml – sequence: 1
  givenname: Daniel H.
  surname: Craighead
  fullname: Craighead, Daniel H.
  organization: The Pennsylvania State University, University Park, Pennsylvania
– sequence: 2
  givenname: Huilei
  surname: Wang
  fullname: Wang, Huilei
  organization: Johns Hopkins University School of Medicine, Baltimore, Maryland
– sequence: 3
  givenname: Lakshmi
  surname: Santhanam
  fullname: Santhanam, Lakshmi
  organization: Johns Hopkins University School of Medicine, Baltimore, Maryland
– sequence: 4
  givenname: Lacy M.
  surname: Alexander
  fullname: Alexander, Lacy M.
  organization: The Pennsylvania State University, University Park, Pennsylvania
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29167120$$D View this record in MEDLINE/PubMed
BookMark eNp9UV1rFDEUDVKx2-ovECTgS19mzcckk7wIpVgVCr7oc8hk7rhZZpI1yazuvzfbdkX74FPCPR-ce88FOgsxAEKvKVlTKtg7u91twKayJkQwumaEds_QqiKsoYLrM7QiXPJGUi7O0UXOW1KJneQv0DnTVHaUkRWK124pgKdDPkw4_vKDzYB92PjeFx8DtlOBlPHsXYp7m90y2YTHJbh71AccYppjgZD9HnC_lDooeHPYQToNZ6g2YcA_Y_29RM9HO2V49fheom-3H77efGruvnz8fHN917iW89LoVmquleiUHYduVL1TvaaUjlbRgWvBgOtBWKGpGIhSvWyh1ZY6omQnmQN-id4_-O6WfobBQSjJTmaX_GzTwUTrzb9I8BvzPe6NUFozyavB1aNBij8WyMXMPjuYJhsgLtlQLTslCRekUt8-oW7jkkJdzzDCKNNE6Lay3vyd6E-UUxeVoB8I9dQ5JxiN88Ue71wD-slQYo69m1Pv5r53c-y9avkT7cn-f6rf2Ne2JQ
CitedBy_id crossref_primary_10_1016_j_bbadis_2019_165645
crossref_primary_10_1038_s44161_023_00311_0
crossref_primary_10_1152_ajpcell_00176_2023
crossref_primary_10_1152_ajpheart_00602_2021
crossref_primary_10_1152_ajpheart_00729_2017
crossref_primary_10_1152_ajpheart_00179_2020
crossref_primary_10_1002_adtp_201900119
crossref_primary_10_3390_ijms21165913
crossref_primary_10_1152_ajpheart_00177_2020
crossref_primary_10_1155_2022_5299370
crossref_primary_10_1152_ajpheart_00404_2021
crossref_primary_10_3389_fphys_2021_746278
crossref_primary_10_1152_ajpheart_00631_2018
Cites_doi 10.1161/01.ATV.0000160548.78317.29
10.1016/j.atherosclerosis.2003.11.015
10.1074/jbc.M210144200
10.1111/j.0022-202X.2004.22330.x
10.1152/japplphysiol.00575.2014
10.1177/1708538113478741
10.1016/j.jvs.2005.05.019
10.1113/jphysiol.2007.128959
10.3892/mmr.2016.5474
10.1136/hrt.2004.053074
10.1007/BF02505035
10.1161/HYPERTENSIONAHA.107.089391
10.1016/j.mvr.2013.02.005
10.1042/CS20120619
10.1093/ajh/hpx127
10.1097/HJH.0b013e328364ca4c
10.1177/000331976801900705
10.1152/japplphysiol.00498.2017
10.1113/JP270062
10.1161/CIR.0000000000000485
10.1097/00004872-198702000-00013
10.1161/HYP.0000000000000018
10.1152/ajpheart.00232.2013
10.1152/japplphysiol.01354.2011
10.1371/journal.pone.0124013
10.1021/acs.jmedchem.7b00345
10.1158/0008-5472.CAN-04-1543
10.1161/01.CIR.0000038109.84500.1E
10.1161/HYPERTENSIONAHA.108.125278
10.1002/jcb.10413
10.1158/0008-5472.CAN-06-3197
10.15252/embj.201489975
10.1016/S0014-2999(02)02825-X
10.1152/japplphysiol.00858.2007
10.1016/j.tips.2006.07.008
10.1158/0008-5472.CAN-05-1274
10.1002/1097-4644(20000915)78:4<550::AID-JCB4>3.0.CO;2-8
10.1161/01.CIR.64.4.760
10.1161/01.ATV.0000033818.21748.99
10.1152/ajpheart.00262.2004
10.1161/ATVBAHA.114.303534
10.1016/j.cellsig.2015.07.001
10.1093/cvr/cvn102
10.1016/0304-4165(92)90095-C
10.1161/HYPERTENSIONAHA.111.178129
10.1161/CIRCRESAHA.116.303596
10.1016/0022-4804(79)90134-3
10.1161/01.HYP.14.2.177
10.1158/0008-5472.CAN-12-2447
10.1152/ajpregu.00269.2014
10.1016/j.ajpath.2014.11.009
10.1111/micc.12382
10.1161/01.HYP.13.6.870
10.1152/japplphysiol.01257.2011
10.1161/01.HYP.0000107251.49515.c2
10.1161/01.HYP.34.4.724
10.1152/japplphysiol.00918.2015
ContentType Journal Article
Copyright Copyright American Physiological Society Mar 2018
Copyright © 2018 the American Physiological Society 2018 American Physiological Society
Copyright_xml – notice: Copyright American Physiological Society Mar 2018
– notice: Copyright © 2018 the American Physiological Society 2018 American Physiological Society
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7QR
7TS
7U7
8FD
C1K
FR3
P64
7X8
5PM
DOI 10.1152/ajpheart.00521.2017
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Physical Education Index
Toxicology Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Technology Research Database
Toxicology Abstracts
Chemoreception Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Physical Education Index
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList Technology Research Database

MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
DocumentTitleAlternate LOX INHIBITION AND MICROVASCULAR FUNCTION
EISSN 1522-1539
EndPage H433
ExternalDocumentID PMC5899263
29167120
10_1152_ajpheart_00521_2017
Genre Comparative Study
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIDDK NIH HHS
  grantid: T32 DK007135
– fundername: NHLBI NIH HHS
  grantid: R01 HL093238
– fundername: ; ;
  grantid: R01 HL093238-07
– fundername: ;
  grantid: Predoctoral Research Grant
GroupedDBID ---
23M
2WC
39C
3O-
4.4
53G
5GY
5VS
6J9
8M5
AAFWJ
AAYXX
ABJNI
ACBEA
ACIWK
ACPRK
ADBBV
AENEX
AFFNX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BKKCC
BKOMP
BTFSW
C1A
CITATION
E3Z
EBS
EJD
EMOBN
F5P
GX1
H13
ITBOX
KQ8
OK1
P2P
PQQKQ
RAP
RHI
RPL
RPRKH
TR2
UKR
W8F
WH7
WOQ
XSW
YSK
YYP
~02
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7QR
7TS
7U7
8FD
C1K
FR3
P64
7X8
5PM
ID FETCH-LOGICAL-c433t-9469398578afd7f8bc8b9111fa81d3952e39d5a5915d088b64e49a1c086762ce3
ISSN 0363-6135
1522-1539
IngestDate Thu Aug 21 14:14:31 EDT 2025
Thu Jul 10 21:29:25 EDT 2025
Mon Jun 30 16:49:00 EDT 2025
Mon Jul 21 06:05:50 EDT 2025
Tue Jul 01 01:16:35 EDT 2025
Thu Apr 24 23:02:28 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords lysyl oxidase
microvascular
hypertension
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c433t-9469398578afd7f8bc8b9111fa81d3952e39d5a5915d088b64e49a1c086762ce3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
OpenAccessLink https://www.physiology.org/doi/pdf/10.1152/ajpheart.00521.2017
PMID 29167120
PQID 2021290594
PQPubID 48261
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5899263
proquest_miscellaneous_1967860350
proquest_journals_2021290594
pubmed_primary_29167120
crossref_citationtrail_10_1152_ajpheart_00521_2017
crossref_primary_10_1152_ajpheart_00521_2017
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-03-01
PublicationDateYYYYMMDD 2018-03-01
PublicationDate_xml – month: 03
  year: 2018
  text: 2018-03-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Bethesda
– name: Bethesda, MD
PublicationSeriesTitle Extracellular Matrix in Cardiovascular Pathophysiology
PublicationTitle American journal of physiology. Heart and circulatory physiology
PublicationTitleAlternate Am J Physiol Heart Circ Physiol
PublicationYear 2018
Publisher American Physiological Society
Publisher_xml – name: American Physiological Society
References B20
B21
B22
B23
B24
B25
Rush JW (B47) 2007; 37
B26
B27
B28
B29
B30
B31
B32
B33
B34
B35
B37
B38
B39
B1
B2
B3
B4
B5
B6
B7
B8
Gillespie CD (B18) 2013; 62
B40
B41
B42
B43
B44
B45
B46
B48
B49
Nakashima Y (B36) 1992; 140
Cox RH (B9) 1988; 25
B50
B51
B52
B53
B10
B54
B11
B55
B12
B56
B13
B57
B14
B15
B59
B16
B17
B19
B60
B61
B62
29351472 - Am J Physiol Heart Circ Physiol. 2018 Apr 1;314(4):H784-H786
References_xml – ident: B62
  doi: 10.1161/01.ATV.0000160548.78317.29
– ident: B15
  doi: 10.1016/j.atherosclerosis.2003.11.015
– ident: B24
  doi: 10.1074/jbc.M210144200
– ident: B38
  doi: 10.1111/j.0022-202X.2004.22330.x
– volume: 62
  start-page: 144
  year: 2013
  ident: B18
  publication-title: MMWR Suppl
– ident: B21
  doi: 10.1152/japplphysiol.00575.2014
– ident: B28
  doi: 10.1177/1708538113478741
– ident: B1
  doi: 10.1016/j.jvs.2005.05.019
– ident: B22
  doi: 10.1113/jphysiol.2007.128959
– ident: B60
  doi: 10.3892/mmr.2016.5474
– ident: B50
  doi: 10.1136/hrt.2004.053074
– ident: B17
  doi: 10.1007/BF02505035
– ident: B59
  doi: 10.1161/HYPERTENSIONAHA.107.089391
– ident: B53
  doi: 10.1016/j.mvr.2013.02.005
– ident: B19
  doi: 10.1042/CS20120619
– ident: B11
  doi: 10.1093/ajh/hpx127
– ident: B33
  doi: 10.1097/HJH.0b013e328364ca4c
– ident: B51
  doi: 10.1177/000331976801900705
– ident: B52
  doi: 10.1152/japplphysiol.00498.2017
– ident: B20
  doi: 10.1113/JP270062
– ident: B5
  doi: 10.1161/CIR.0000000000000485
– ident: B39
  doi: 10.1097/00004872-198702000-00013
– ident: B43
  doi: 10.1161/HYP.0000000000000018
– volume: 140
  start-page: 959
  year: 1992
  ident: B36
  publication-title: Am J Pathol
– ident: B49
  doi: 10.1152/ajpheart.00232.2013
– ident: B6
  doi: 10.1152/japplphysiol.01354.2011
– ident: B13
  doi: 10.1371/journal.pone.0124013
– ident: B45
  doi: 10.1021/acs.jmedchem.7b00345
– ident: B26
  doi: 10.1158/0008-5472.CAN-04-1543
– ident: B31
  doi: 10.1161/01.CIR.0000038109.84500.1E
– ident: B30
  doi: 10.1161/HYPERTENSIONAHA.108.125278
– ident: B25
  doi: 10.1002/jcb.10413
– ident: B14
  doi: 10.1158/0008-5472.CAN-06-3197
– ident: B34
  doi: 10.15252/embj.201489975
– volume: 25
  start-page: 53
  year: 1988
  ident: B9
  publication-title: Blood Vessels
– ident: B16
  doi: 10.1016/S0014-2999(02)02825-X
– ident: B23
  doi: 10.1152/japplphysiol.00858.2007
– ident: B10
  doi: 10.1016/j.tips.2006.07.008
– ident: B40
  doi: 10.1158/0008-5472.CAN-05-1274
– ident: B29
  doi: 10.1002/1097-4644(20000915)78:4<550::AID-JCB4>3.0.CO;2-8
– ident: B35
  doi: 10.1161/01.CIR.64.4.760
– ident: B42
  doi: 10.1161/01.ATV.0000033818.21748.99
– ident: B48
  doi: 10.1152/ajpheart.00262.2004
– ident: B37
  doi: 10.1161/ATVBAHA.114.303534
– ident: B55
  doi: 10.1016/j.cellsig.2015.07.001
– volume: 37
  start-page: 185
  year: 2007
  ident: B47
  publication-title: Clin Hemorheol Microcirc
– ident: B41
  doi: 10.1093/cvr/cvn102
– ident: B46
  doi: 10.1016/0304-4165(92)90095-C
– ident: B54
  doi: 10.1161/HYPERTENSIONAHA.111.178129
– ident: B27
  doi: 10.1161/CIRCRESAHA.116.303596
– ident: B3
  doi: 10.1016/0022-4804(79)90134-3
– ident: B2
  doi: 10.1161/01.HYP.14.2.177
– ident: B4
  doi: 10.1158/0008-5472.CAN-12-2447
– ident: B57
  doi: 10.1152/ajpregu.00269.2014
– ident: B44
  doi: 10.1016/j.ajpath.2014.11.009
– ident: B12
  doi: 10.1111/micc.12382
– ident: B61
  doi: 10.1161/01.HYP.13.6.870
– ident: B56
  doi: 10.1152/japplphysiol.01257.2011
– ident: B8
  doi: 10.1161/01.HYP.0000107251.49515.c2
– ident: B32
  doi: 10.1161/01.HYP.34.4.724
– ident: B7
  doi: 10.1152/japplphysiol.00918.2015
– reference: 29351472 - Am J Physiol Heart Circ Physiol. 2018 Apr 1;314(4):H784-H786
SSID ssj0005763
Score 2.3195615
Snippet The lysyl oxidase (LOX) family of enzymes regulates collagen cross-linking. LOX is upregulated in hypertension, increasing vascular stiffness. In vivo human...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage H424
SubjectTerms Adult
Age
Amino Acid Oxidoreductases - antagonists & inhibitors
Amino Acid Oxidoreductases - metabolism
Aminopropionitrile - administration & dosage
Blood Pressure
Collagen
Conductance
Cross-linking
Crosslinking
Doppler effect
Enzyme Inhibitors - administration & dosage
Erythrocytes
Extracellular matrix
Female
Fibers
Forearm
Humans
Hypertension
Hypertension - diagnosis
Hypertension - physiopathology
Inhibition
Liquid oxygen
Lysyl oxidase
Male
Matrix
Men
Microcirculation - drug effects
Microdialysis
Microvasculature
Microvessels - drug effects
Microvessels - enzymology
Microvessels - physiopathology
Middle Aged
Muscles
Norepinephrine
Oxidase
Protein-Lysine 6-Oxidase - antagonists & inhibitors
Protein-Lysine 6-Oxidase - metabolism
Skin
Skin - blood supply
Smooth muscle
Sodium
Sodium nitroprusside
Stability
Stability analysis
Stiffness
Vasoconstriction - drug effects
Vasodilation - drug effects
Women
Young Adult
Title Acute lysyl oxidase inhibition alters microvascular function in normotensive but not hypertensive men and women
URI https://www.ncbi.nlm.nih.gov/pubmed/29167120
https://www.proquest.com/docview/2021290594
https://www.proquest.com/docview/1967860350
https://pubmed.ncbi.nlm.nih.gov/PMC5899263
Volume 314
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBAvCDYuhYGMhHgpCW0Sp_FjhUARMATSJu0tShxHzVjTqU0lyn_lv_DZTpx0mybGS1TZrtP0fDn3c0zIm8IvwoyF0hF5WDhBOJFOFgnpyECMRRhlPNVnAx59C-OT4PMpOx0M_vSyljZ15orf19aV_A9VMQa6qirZW1DWbooBfAZ9cQWFcf0nGs-EivKfb9dbaJS_yhwSaVRW8zIrzfnfKhK-Hi1Uzp3NOFWCrE1wrKCwLm0K-6bGQD2awzJdtYMLaZKVdaOGviJrIz291hPaS6Ld9K4qb1qZ5HVRrtSddTC_W2FjH6tUZZqkeVfvPordzs1vWFG8AfMqrTcIaJinlYHy1_Tner6wc7Zgx8yJ7ejI7Xs2JlGX2mUrunyYtqadiSsbBg3jGVya9zm4b-pQG6j6PX4cB6ZCu5HtcWC6blyVG0z1oU3PLtQx4rWrnOXKeWDKSne7dF-SnjanUVtTzEvaTRK9SaI2uUPuerBilNz48qNrZg9Tz29D6eoxm6ZY2OT9Nb9kV3G6Yg1dTurtaUnHD8mDxryhM4PVR2Qgq31yMKtA_sWWvqXfLQD2yb2jJq_jgCw1kqlGMm2QTDskU4NkuoNk2iIZC2kfyRRIxkBN-0imwC8FMKhG8mNy8unj8YfYaY4CcQRIVjs8CLnPI4iXtMinRZQJsBGI6SKFveVz5kmf5yxlfMJyyM0sDGQANiNgsEPaC-k_IXvVspLPCOUiSid5NvbEuIB6GmU5TGwRBUwdnSCLfEi89n9ORNMnXx3Xcp7cQOEheWe_dGHaxNy8_LAlYNK8pmtMeMopzHgwJK_tNLi9CuGllVxu1gnk5TQKVTbAkDw19Lb382DpTSceZqY7SLALVCf53ZmqnOuO8izi3Av957d7ihfkfvfaHpK9erWRL6Gi19krDfS_Mcvw6Q
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Acute+lysyl+oxidase+inhibition+alters+microvascular+function+in+normotensive+but+not+hypertensive+men+and+women&rft.jtitle=American+journal+of+physiology.+Heart+and+circulatory+physiology&rft.au=Craighead%2C+Daniel+H.&rft.au=Wang%2C+Huilei&rft.au=Santhanam%2C+Lakshmi&rft.au=Alexander%2C+Lacy+M.&rft.date=2018-03-01&rft.issn=0363-6135&rft.eissn=1522-1539&rft.volume=314&rft.issue=3&rft.spage=H424&rft.epage=H433&rft_id=info:doi/10.1152%2Fajpheart.00521.2017&rft.externalDBID=n%2Fa&rft.externalDocID=10_1152_ajpheart_00521_2017
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0363-6135&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0363-6135&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0363-6135&client=summon